Please ensure Javascript is enabled for purposes of website accessibility

Therapeutics Acquisition Corp. Jumps 22% in IPO Debut

By Brian Orelli, PhD - Jul 8, 2020 at 6:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The special purpose acquisition company is sponsored by RA Capital Management.

Shares of Therapeutics Acquisition Corp. (TXAC) flew out of the gates today, rising 22% on its first day on the market.

Not bad for a company that doesn't own any drugs or even any drug candidates -- at the moment, at least.

Therapeutics Acquisition Corp. is a special purpose acquisition company (SPAC), sometimes referred to as a "blank check" company because investors are basically giving management a blank check to go out and buy something.

In this case, chairman and CEO Peter Kolchinsky and CFO Matthew Hammond will look to combine Therapeutics Acquisition Corp. with one or more businesses in the healthcare industry. Therapeutics Acquisition Corp. will bring over $100 million in cash, while the other company or companies contribute their assets.

Arms shaking hands

Image source: Getty Images.

Kolchinsky co-founded RA Capital Management, which is sponsoring the SPAC, and Hammond works at RA as well, serving as a principal. With the help of RA's venture capital arm, Kolchinsky and Hammond shouldn't have too much trouble finding a company in need of capital and looking to go public. If the duo can't find a deal within 24 months, the certificate of incorporation calls for the redemption of the public shares.

By purchasing shares 22% higher than the IPO price, investors are essentially buying $0.77 on the $1 after factoring in underwriting discounts and commissions. Ultimately investors seem to think Kolchinsky and Hammond will be able to find under-priced assets that can bring immediate value to shareholders of the SPAC.

Happy hunting.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Therapeutics Acquisition Corp Stock Quote
Therapeutics Acquisition Corp
TXAC

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.